PALO ALTO, Calif., Sept. 27, 2023 /PRNewswire/ -- Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan. Under the terms of the agreement, Evommune is eligible to receive up to $60 million in upfront and customary milestone payments. In addition, Evommune is eligible to receive meaningful royalties on future sales of EVO756 in Japan.
WILMINGTON, Del. & OSAKA, Japan--(BUSINESS WIRE)--Incyte (NASDAQ:INCY) and Maruho Co., Ltd. today announced that the companies have entered into a Strategic Alliance Agreement for the development, manufacturing and exclusive commercialization of ruxolitinib cream, a novel cream formulation of Incyte’s selective JAK2 inhibitor ruxolitinib, for treatment of autoimmune and inflammatory dermatology indications in Japan.
Chugai Pharmaceutical Co., Ltd. announced that Maruho Co., Ltd. obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for the anti-IL-31 receptor A humanized monoclonal antibody Mitchga subcutaneous injection 60 mg syringes [generic name: nemolizumab (genetical recombination)] for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective).
BRANFORD, Conn. and NESS ZIONA, Israel, Oct. 13, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target specific pathogenic bacteria, announced today that it has entered into an agreement granting Maruho Co. Ltd
TOKYO, July 9, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that results from a phase III study conducted by Maruho Co., Ltd. investigating nemolizumab in atopic dermatitis patients 13 years of age or older with moderate-to-severe pruritus were published in The New England Journal of Medicine Online. Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai.
Excelra (www.excelra.com), a leading global Data and Analytics Company today announced a Drug Repurposing collaboration with Osaka-based Maruho – a pharmaceutical company specialising in Dermatology.
Japan based Solasia Pharma K.K. has announced that it has entered into an exclusive license agreement with Maruho Co., Ltd. for the commercialization of Solasia’s product SP-04 (PledOx®), a therapeutic agent for chemotherapy induced peripheral neuropathy (currently undergoing Phase III clinical trials; active ingredient name: calmangafodipir) in Japan.